| High-density lipoprotein therapy: is there hope? | |
| | |
MedLine Citation:
|
PMID: 20842556 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
OPINION STATEMENT: The treatment of lipid abnormalities generally has focused on low-density lipoprotein cholesterol (LDL-C) reduction based on extensive clinical trials and the National Cholesterol Education Program Adult Treatment Panel III guidelines. Unfortunately, it has become increasingly clear that a significant percentage of patients continue to have cardiovascular events despite being on LDL-C-lowering medications and having LDL-C levels below 100 mg/dL. Numerous epidemiologic studies have associated low high-density lipoprotein cholesterol (HDL-C) levels with increased risk of cardiovascular disease (CVD). Furthermore, recent data show that up to 55% of patients hospitalized for CVD have low HDL-C levels (<40 mg/dL) on admission, suggesting a possible target for further reducing CVD. Low HDL-C also is part of the atherogenic phenotype associated with obesity, glucose intolerance, and hypertension, termed the metabolic syndrome, and often is seen in patients with insulin resistance states. In general, the first line of therapy for increasing HDL-C in patients with levels below 40 mg/dL is lifestyle modification with smoking cessation, exercise, weight loss, and diet modifications. The pharmacologic treatment of isolated low HDL-C in patients without coronary disease is controversial but should be considered in those with a strong family history of CVD. In patients with coronary artery disease and isolated low HDL-C, statins remain the first-line therapy and should be instituted after lifestyle modifications, with the goal of increasing HDL-C above 40 mg/dL. If concomitant hypertriglyceridemia is present, a fibrate or niacin should be considered. Although statins do offer some HDL-C-raising properties, they tend to have modest effects. If treatment goals have not been achieved with either lifestyle changes or statin therapy, then the next agent of choice is niacin. Among the various HDL-C-raising therapies, niacin continues to be the most potent therapeutic option available. There are several novel HDL-C therapies in the research pipeline; however, only one class of medications is relatively close to clinical use, the cholesteryl ester transferase protein (CETP) inhibitors. Although one of the CETP inhibitors, torcetrapib, has received much negative attention from a large randomized trial showing increased mortality associated with its use, the overall class of therapeutic agents may still hold some benefit. Currently, two new CETP inhibitors without the off-target effects of torcetrapib are undergoing clinical research. Overall, the use of HDL-C-modifying agents likely will increase over the next decade. |
| | |
Authors:
|
Kunal N Bhatt; Bryan J Wells; Laurence S Sperling; Jefferson T Baer |
Related Documents
:
|
19570586 - Pivotal role of inflammation in vascular endothelial dysfunction of hyperlipidemic rabb... 20451686 - Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescri... 11009276 - High-density lipoprotein cholesterol and triglyceride response with simvastatin versus ... 3069436 - Lovastatin. a preliminary review of its pharmacodynamic properties and therapeutic use ... 20847736 - The effect of electronic self-monitoring on weight loss and dietary intake: a randomize... 19116776 - Diet-induced alterations in intestinal and extrahepatic lipid metabolism in liver fatty... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current treatment options in cardiovascular medicine Volume: 12 ISSN: 1534-3189 ISO Abbreviation: Curr Treat Options Cardiovasc Med Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-09-15 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9815942 Medline TA: Curr Treat Options Cardiovasc Med Country: United States |
Other Details:
|
Languages: eng Pagination: 315-28 Citation Subset: - |
Affiliation:
|
Department of Medicine, Division of Cardiology (Section of Preventive Cardiology), Emory University School of Medicine, 1364 Clifton Road, Atlanta, GA, 30322, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Management of Raynaud's Phenomenon in the Patient with Connective Tissue Disease.
Next Document: Exercise as a treatment for the risk of cardiovascular disease.